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Background: The optimal clinical context for initiation of salvage androgen deprivation therapy (SADT) following
the biochemical recurrence of localized prostate cancer remains controversial. We chose to investigate if disease
burden at time of SADT initiation is associated with clinical outcomes following biochemical failure (BF)
post-salvage radiation therapy (SRT).
Methods: Medical records of 575 patients receiving SRT at a single institution from 1986–2010 were retrospectively
reviewed. Of 250 patients experiencing BF post-SRT, 172 had a calculable prostate-specific antigen doubling time
(PSADT) prior to SADT initiation. These patients comprise the analyzed cohort and were divided into four groups
based on characteristics at SADT initiation: those with PSADTs >3 months without distant metastasis (DM) (group 1
[less advanced disease], n = 62), those with PSADTs <3 months without DM (group 2 [more advanced disease],
n = 28), those with DM (group 3 [more advanced disease], n = 32), and those not receiving SADT during follow-up
(group 4, n = 50). Endpoints included prostate cancer-specific mortality (PCSM) and overall mortality (OM).
Kaplan-Meier methods were used to estimate survival, and Cox proportional hazards models were used for
multivariate analysis.
Results: Median follow-up post-SRT was 7.9 years. Patients starting SADT with more advanced disease were at
significantly increased risk for PCSM (hazard ratio [HR]:2.8, 95% confidence interval [CI]: 1.4–5.6, p = 0.005) and OM
(HR:1.9, 95% CI: 1.0–3.5, p = 0.04) compared to those receiving SADT with less advanced disease. PCSM and OM did
not significantly differ between groups 1 and 4 or groups 2 and 3. Of note, patients in group 4 had very long
PSADTs (median = 27.0 months) that were significantly longer than those of group 1 (median = 6.0 months)
(p < 0.001). Multivariate analysis including groups 1–3 found a pre-SADT PSADT <3 months to be the most
significant predictor of PCSM (HR:4.2, 95% CI: 1.6–11.1, p = 0.004) and the only significant predictor of OM (HR:2.9,
95% CI: 1.3–6.7, p = 0.01).
Conclusions: Less advanced disease at initiation of SADT is associated with decreased PCSM and OM following BF
post-SRT; however, observation may be reasonable for patients with very long PSADTs. A PSADT <3 months prior
to SADT initiation significantly predicts an increased risk of PCSM and OM in this patient demographic.
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It is estimated that the majority of patients receiving sal-
vage radiation therapy (SRT) for biochemically recurrent
prostate cancer post-radical prostatectomy (RP) will not
achieve long-term disease control [1]. Eventually, many
such patients will once again develop a rising prostate-
specific antigen (PSA) after radiotherapy (RT), suggest-
ing the presence of residual local or metastatic disease.
Having exhausted their options for local therapy, only
systemic treatments remain for these patients with re-
currence post-SRT. One common intervention in this
setting is the initiation of salvage androgen deprivation
therapy (SADT).
While SADT is clearly beneficial for metastatic pros-
tate cancer [2] and initiating SADT while disease burden
is low in the setting of advanced disease appears to be
clinically advantageous [3], the optimal clinical context
for initiation of SADT following the development of bio-
chemical failure (BF) in the absence of metastatic disease
remains controversial [4,5]. Much of this controversy
stems from the lack of prospective, randomized trials
investigating the potential benefits of initiating SADT
while disease burden is low for patients experiencing BF
alone after local treatment [4,6]. Nonetheless, retrospect-
ive studies have consistently suggested that beginning
SADT early in the clinical course of recurrent disease
post-definitive RT is associated with improved overall
survival [7-11]. The purpose of this retrospective analysis
is to assess whether less advanced disease at initiation of
SADT is similarly associated with improved clinical out-
comes following BF post-SRT.
Methods
Patient selection
The medical records of 575 patients receiving SRT with
or without concurrent androgen deprivation therapy
(ADT) at a single institution from 1986 to 2010 were
retrospectively reviewed in an institutional review board-
approved analysis. SRT was defined as any post-RP RT
for a persistently elevated PSA post-RP or for BF post-
RP as defined by the American Urologic Association
[12]. Of the 575 patients receiving SRT, 250 (43%) went
on to experience BF, with BF post-SRT defined as the
development of a PSA value 0.2 ng/mL or more above
the post-SRT PSA nadir followed by another higher PSA
value [1] or any single post-SRT PSA value of 0.5 ng/mL
or greater. A total of 172 patients who experienced BF
post-SRT had a calculable prostate-specific antigen doub-
ling time (PSADT) prior to starting SADT, and they com-
prise the cohort used for this analysis. Of these patients,
122 (70%) went on to receive SADT, which was defined as
any ADT given after the development of BF or distant
metastasis (DM) following SRT. PSADTs were calculated
as previously described [13]. A minimum of 3 consecutivePSA values preceding the initiation of SADT was required
for the calculation of pre-SADT PSADT, and all available
PSA values following BF post-SRT were included in the
calculation of PSADTs for patients not receiving SADT
during follow-up.
The study was conducted after IRB approval at the
University of Michigan Medical Center (Ann Arbor, MI).
Treatment
Three-dimensional conformal RT or intensity-modulated
RT was used for SRT delivery with greater than 95% of
patients receiving an SRT dose between 64.0–70.2 Gy.
Sixteen patients (9.3%) received whole-pelvic RT. Twenty-
five patients (14.5%) received concurrent ADT during SRT.
The decision of whether or not to prescribe concurrent
ADT with SRT was made on an individual basis after con-
sideration of clinical and pathologic risk factors. The type
of SADT given and the timing of SADT initiation following
BF post-SRT were at the discretion of the treating phys-
ician. When starting SADT, the most frequently prescribed
options included a gonadotropin-releasing hormone agon-
ist alone or a gonadotropin-releasing hormone agonist in
combination with a non-steroidal antiandrogen. These
regimens were given to 39% and 30% of patients receiving
SADT, respectively.
Endpoints
Primary outcomes included prostate cancer-specific mor-
tality (PCSM) and overall mortality (OM). PCSM was
defined as any death in the setting of metastatic prostate
cancer or castration resistant disease as well as any death
otherwise attributed to prostate cancer. OM was defined
as death from all causes.
Statistical analysis
Patients were stratified into four groups based on
whether or not SADT was initiated, pre-SADT PSADT,
and the presence or absence of DM at the time of SADT
initiation. Patients with a PSADT >3 months in the ab-
sence of known DM prior to starting SADT were con-
sidered to have less advanced disease at SADT initiation.
Those with known DM or a PSADT <3 months without
DM upon SADT initiation were considered to have more
advanced disease at SADT initiation. Pre-SADT PSADT
was chosen as a discriminatory clinical characteristic when
determining disease burden at initiation of SADT because
of the previously described ability of a short post-treatment
PSADT to predict poor clinical outcomes following RP
[13-16], definitive RT [15,16], and SRT [1,17], implying that
patients with shorter PSADTs have more advanced disease.
A cut-point of 3 months was chosen for stratification of
pre-SADT PSADTs as it is was the closest commonly
reported threshold to our median PSADT of 4.4 ng/mL
and because a post-treatment PSADT <3 months has been
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suggesting patients with PSADTs below this threshold
may have a higher disease burden [15,16].
Univariate survival analyses were performed using
Kaplan-Meier methods and log-rank tests. The methods
of Harrell et al. were used to calculate concordance indi-
ces (c-indices) with ties being awarded one half their value
[18]. Cox proportional hazards models were used for
multivariate analysis. Survival was analyzed from the time
of BF post-SRT to avoid potential lead-time bias asso-
ciated with analyzing survival from the start of SADT.
All statistical analyses were performed using MedCalc
(v 12.7.8, MedCalc Software, Ostend, Belgium).
Results
Patient characteristics
The 172 patients in the cohort used for analysis had
a median follow-up of 7.9 years (interquartile range
[IQR]: 5.7–10.9) following SRT. Sixty-two patients having
PSADTs >3 months without DM prior to starting SADT
were included in group 1. Group 2 included 28 patients
with PSADTs <3 months and no DM before SADT
administration while group 3 consisted of 32 patients
with known DM preceding initiation of SADT. Fifty-
five patients not receiving SADT or other salvage therapies
during follow-up comprised group 4. Group 1 was consid-
ered to have less advanced disease at initiation of SADT
whereas patients in groups 2 and 3 were considered to
have more advanced disease at initiation of SADT.
Pre-treatment, treatment, and pathologic characteris-
tics stratified by patient group are displayed in Table 1.
Significant differences among the four groups included a
lower percentage of patients with Gleason scores of
8–10 in groups 1 and 4 (p = 0.04), a higher percentage of
patients with Gleason scores of 2–6 in group 4 (p = 0.04),
and a lower percentage of patients with an undetectable
PSA nadir post-SRT in group 4 (p = 0.005). Patients in
group 4 had a median follow-up post-BF of 3.6 years
(range: 0.4–15.3) and notably long PSADTs following BF
post-SRT (median = 27.0 months, IQR: 13.6–47.7). The
PSADTs of this group were statistically significantly longer
than those in groups 1–3 (p < 0.001) and those in group 1
alone (p < 0.001). Additionally, the interval to biochemical
failure (IBF) after beginning SRT for group 4 was signifi-
cantly longer than the IBF for other groups (p < 0.001),
and the percentage of patients with a short IBF (de-
fined as <18 months [19]) was significantly lower as well
(p < 0.0001). There was no statistically significant differ-
ence in the length of IBF or percentage of patients
with an IBF <18 months among groups 1–3. Patients in
groups 1–3 with a short IBF experienced BF a median of
7.9 months (mean = 9.0) after starting SRT and had a
median pre-SADT PSADT of 4.4 months (IQR: 2.4–6.1)
while those with a long IBF experienced BF a median of29.8 months (mean = 33.2) after starting SRT and had a
median pre-SADT PSADT of 5.8 months (IQR: 2.7–9.1)
(p = 0.04). Other pertinent pathologic characteristics did
not differ significantly among the four groups.
Univariate analysis
Kaplan-Meier survival curves displaying the prostate-
cancer specific survival and overall survival of groups 1–4
are displayed in Figure 1. PCSM significantly differed
among the four groups (p = 0.001) with 5-year rates of
PCSM being 4%, 24%, 13%, and 0% for groups 1–4, re-
spectively; however, OM was not significantly different
among the four subsets of patients. There was no sta-
tistically significant difference in PCSM or OM when
comparing groups 1 and 4 or groups 2 and 3. Of note,
patients categorized as having more advanced disease at
initiation of SADT were at statistically significantly in-
creased risk for PCSM (HR:2.8, 95% CI: 1.4–5.6, p = 0.005)
and OM (HR:1.9, 95% CI: 1.0–3.5, p = 0.04) when com-
pared to those with less advanced disease at initiation of
SADT. In addition, a Kaplan-Meier curve depicting the
amount of time between BF and SADT initiation strati-
fied by groups 1–3 is displayed in Figure 2. Patients in
group 2 were found to receive SADT significantly more
quickly than patients in group 1 (p = 0.03).
When using a univariate Cox proportional hazards re-
gression including groups 1–3, PSADT at initiation of
SADT as a continuous variable was found to be signi-
ficantly prognostic for PCSM (hazard ratio [HR]:0.8, 95%
confidence interval [CI]: 0.7–0.9, p = 0.0009) and OM
(HR:0.9, 95% CI: 0.8–0.96, p = 0.01). PSA level immedi-
ately before starting SADT was also significantly predict-
ive of PCSM (HR:1.02, 95% CI: 1.01–1.03, p = 0.002) and
OM (HR:1.02, 95% CI: 1.01–1.03, p = 0.002) on univariate
Cox proportional hazards regression. C-indices were cal-
culated for pre-SADT PSADT as a continuous variable
given its strong prognostic ability and found to be 0.74 for
PCSM and 0.71 for OM.
Multivariate analysis
Multivariate analysis including groups 1–3 was perfor-
med while controlling for pre-SADT PSA, pre-SADT
PSADT <3 months, DM at SADT initiation, achievement
of an undetectable PSA nadir post-SRT, total Gleason
score, seminal vesicle invasion, extracapsular extension,
presence of any positive surgical margin, use of ADT dur-
ing SRT, start date of SRT, Charlson Comorbidity Index at
the time of SRT [20], and interval to biochemical fail-
ure (IBF) <18 months following the start of SRT [19].
Table 2 displays the results of a Cox proportional
hazards model including these covariates and shows
that a PSADT <3 months prior to initiation of SADT was
the most significant predictor of PCSM (HR:4.2, 95% CI:
1.6–11.1, p = 0.004) and only significant predictor of OM
Table 1 Pre-treatment, treatment, and pathologic characteristics stratified by patient group
Group 1 (PSADT >3 months,
DM absent at start of SADT)
(n = 62)
Group 2 (PSADT <3 months,
DM absent at start of SADT)
(n = 28)
Group 3 (DM present
at start of SADT)
(n = 32)
Group 4 (No SADT)
(n = 50)
Age at SRT (y),
median (IQR)
65.7 (58.9–70.4) 63.0 (56.6–67.3) 63.6 (57.8–67.6) 62.3 (55.9–67.5) p = 0.38*
CCMI, median
(range) (n = 147)
3.0 (1.0–6.0) 3.0 (1.0–6.0) 3.0 (1.0–5.0) 3.0 (1.0–5.0) p = 0.49*
Pre-SRT PSA (ng/mL),
median (IQR) (n = 163)
0.9 (0.5–1.7) 1.0 (0.5–1.5) 0.6 (0.3–1.0) 0.5 (0.4–0.7) p = 0.09*
SRT dose (Gy), median
(IQR) (n = 171)
68.4 (64.8–68.4) 65.8 (64.8–68.4) 68.4 (64.8–68.4) 64.9 (64.8–68.4) p = 0.22*
WPRT 11.3% 3.6% 12.5% 8.0% p = 0.60**
ADT during SRT 12.9% 25.0% 12.5% 12.0% p = 0.40**
Duration of ADT during
SRT (mo), median (IQR)
6.4 (6.0–19.6) 6.2 (3.6–11.1) 6.0 (3.6–7.8) 6.0 (3.0–12.0) p = 0.43*
Gleason score (n = 171)
2–6 9.8% 7.1% 3.1% 22.0% p = 0.04**
7 63.9% 42.9% 53.1% 54.0% p = 0.30**
8–10 26.2% 50.0% 43.8% 24.0% p = 0.04**
pT stage (n = 146)
T1-T2a 10.4% 0.0% 3.3% 4.7% p = 0.26**
T2b-T2c 18.8% 12.0% 16.7% 16.3% p = 0.91**
T3-T4 70.8% 88.0% 80.0% 79.1% p = 0.39**
SVI (n = 171) 21.0% 35.7% 34.4% 26.5% p = 0.38**
ECE 54.8% 78.6% 75.0% 70.0% p = 0.07**




69.4% 64.3% 81.30% 45.8% p = 0.008**
PSA before SADT
(ng/mL), median (IQR)
4.3 (2.0–6.7) 2.7 (1.0–8.0) 5.2 (2.4–9.7) --- p = 0.21*
PSADT after SRT (mo),
median (IQR)
6.0 (4.5–9.5) 2.2 (1.5–2.7) 4.1 (1.9–7.3) 27.0 (13.6–47.7) p < 0.001*
IBF (mo), median
(mean)
12.9 (18.1) 11.5 (18.5) 13.6 (13.8) 48.3 (48.7) p < 0.001*
IBF <18 months 61.3% 67.9% 75.0% 12.0% p < 0.0001**
Abbreviations: PSADT = prostate-specific antigen doubling time, SADT = salvage androgen deprivation therapy, DM = distant metastasis, SRT = salvage radiation
therapy, IQR = interquartile range, CCMI = Charlson Comorbidity Index, PSA = prostate-specific antigen, WPRT = whole-pelvic radiation therapy, ADT = androgen
deprivation therapy, pT stage = pathologic T stage, SVI = seminal vesicle invasion, ECE = extracapsular extension, SM = presence of any positive surgical margin,
IBF = interval to biochemical failure, *Analysis of variance, **Chi-square.
Foster et al. Radiation Oncology 2014, 9:245 Page 4 of 9
http://www.ro-journal.com/content/9/1/245(HR:2.9, 95% CI: 1.3–6.7, p = 0.01). Since there is debate
about which PSADT cut-point optimizes its prognostic
ability for poor outcomes, the same multivariate analysis
was performed while including pre-SADT PSADT as a
continuous rather than a categorical variable. Pre-SADT
PSADT as a continuous variable was again the most
significant predictor of PCSM (HR:0.7, 95% CI: 0.6–0.9,
p = 0.01) with an interval to biochemical failure <18 months
also being predictive for this endpoint (HR:4.8, 95% CI:
1.1–19.9, p = 0.03). On the other hand, PSA prior to initi-
ation of SADT was the only significant predictor of OMwhen including pre-SADT PSADTas a continuous variable
(HR:1.0, 95% CI: 1.0–1.0, p = 0.04).
Discussion
We performed a single-institution, retrospective review
examining prognostic factors for PCSM and OM for
men experiencing BF after SRT. These data are limited
by selection bias and their non-randomized nature. Des-
pite these limitations, they suggest a decreased risk of
PCSM and OM associated with the initiation of SADT
while patients have a PSADT >3 months in the absence
Prostate Cancer-Specific Survival
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Figure 1 Kaplan Meier plot of prostate cancer specific survival and overall survival after biochemical failure for patients treated with
salvage radiotherapy. A Displays prostate cancer-specific survival as a function of no use of salvage ADT (SADT) or salvage ADT started after
distant metastasis (DM), or before distant metastasis but stratified by short (<3 months) or long (>3 months) PSA doubling time (PSADT) while B
shows overall survival based upon the same stratifications. B: Kaplan Meier Plot of the Time from BF to the Start of Salvage Androgen Deprivation
Therapy (SADT). Patients are Stratified by their clinical status at the time of receiving (SADT) where some had already experienced distant
metastasis when SADT was started (DM) while others had no DM but were stratified by short (<3 months) or long (>3 months) PSA doubling
time (PSADT).
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between a longer PSADT at SADT initiation and im-
proved clinical outcomes is cause and effect or simplyan association observed in this cohort is unknown.
However, it does not seem unreasonable that initiating
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Figure 2 Time between BF post-SRT and the start of SADT stratified by patient groups 1–3. Abbreviations: SADT = salvage androgen
deprivation therapy, BF = biochemical failure, PSADT = prostate specific-antigen doubling time, SRT = salvage radiation therapy.




Variable HR (95% CI) P HR (95% CI) P
PSA before SADT 1.0 (1.0–1.0) 0.06 1.0 (1.0–1.0) 0.06
Pre-SADT PSADT
<3 months
4.2 (1.6–11.1) 0.004 2.9 (1.3–6.7) 0.01
DM at SADT initiation 1.1 (0.4–3.0) 0.9 0.9 (0.4–2.4) 0.9
Undetectable PSA
nadir post-SRT
0.7 (0.2–2.9) 0.7 0.6 (0.2–1.9) 0.4
Total Gleason score 1.2 (0.7–2.1) 0.5 1.0 (0.6–1.7) 1.0
SVI 1.7 (0.6–5.1) 0.3 1.8 (0.7–4.6) 0.2
ECE 0.5 (0.1–2.0) 0.4 0.8 (0.3–2.4) 0.7
SM 1.5 (0.5–4.6) 0.5 1.0 (0.4–2.7) 1.0
ADT during SRT 1.1 (0.3–4.2) 0.9 1.6 (0.5–5.1) 0.4
Start date of SRT 1.0 (1.0–1.0) 0.4 1.0 (1.0–1.0) 0.1
CCMI 1.2 (0.8–1.9) 0.4 1.0 (0.7–1.5) 0.8
IBF <18 months 5.8 (1.3–24.1) 0.02 2.7 (0.9–7.9) 0.07
Abbreviations: HR = hazards ratio, CI = confidence interval, PSA = prostate-
specific antigen, SADT = salvage androgen deprivation therapy, DM = distant
metastasis, SVI = seminal vesicle invasion, ECE = extracapsular extension,
SM = presence of any positive surgical margin, ADT = androgen deprivation
therapy, SRT = salvage radiation therapy, CCMI = Charlson Comorbidity Index,
IBF = interval to biochemical failure.
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improved clinical outcomes as this is in accordance with a
recent meta-analysis of randomized trials performed in
those with advanced prostate cancer [3]. Our findings are
the first to indicate that less advanced recurrent disease at
the time of SADT initiation post-SRT may be beneficial
and, to our knowledge, no other similar retrospective
studies in the post-SRT setting have been completed to
date. Moreover, prospective trials demonstrating a survival
benefit associated with the initiation of SADT early in the
disease course for patients experiencing BF alone follow-
ing RP, definitive RT, or SRT are lacking [4,6].
Of note, our results do not support initiation of SADT
in all patients with less advanced disease following BF
post-SRT. The lack of a significant difference in PCSM
and OM between patients receiving SADT with a low
disease burden (group 1) and patients not receiving SADT
during follow-up (group 4) suggests that there is a subset
of patients for whom initiating SADT while they have less
advanced disease may not be beneficial. Given the very
long PSADTs and long median IBF for patients in group
4, it is likely that patients experiencing late BF with a grad-
ual, slow rise in PSA may not be reasonable candidates for
initiation of SADT. Freedland et al. discovered that pa-
tients with PSADTs >15 months post-RP were at very low
risk for PCSM, confirming that initiating SADT while
disease burden is low may not be clinically advantageous
for patients with especially long PSADTs [14]. Supporting
this possibility is the fact that, like Freedland et al.,
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PSADT >15 months experienced PCSM. Therefore, it
may be reasonable to initially observe patients with
very long PSADTs after BF post-SRT and reconsider start-
ing SADT should these patients go on to develop short-
ened PSADTs during follow-up. On the other hand, for
patients with PSADTs that are short enough to put them
at a less than negligible risk for PCSM, starting SADT prior
to the development of metastasis or a PSADT <3 months
is associated with a decreased risk of PCSM and OM based
on our findings.
Interestingly, we demonstrated that patients without
DM who do not receive SADT until they have a
PSADT <3 months have a risk of PCSM and OM com-
parable to those who start SADT with known DM, which
is consistent with similar findings in the post-definitive RT
setting [9]. Therefore, patients without DM who do
not receive SADT until they have developed short
PSADTs may already harbor disease that is sufficiently
aggressive to lessen SADT’s therapeutic benefits. Add-
itionally, among patients without DM prior to starting
SADT, those with a pre-SADT PSADT <3 months were
found to be at a significantly increased risk for PCSM and
OM despite having received SADT more quickly than
patients with longer PSADTs. Thus, close monitoring of
PSADT following BF post-SRT may be warranted to
identify even small windows of opportunity to start SADT
before the development of a short PSADT.
In our analysis, PSADT before the initiation of SADT
was shown to be strongly prognostic of both PCSM and
OM on univariate and multivariate analysis. The c-index
value of 0.74 for PCSM and 0.71 for OM is further evi-
dence of the prognostic utility of PSADT prior to start-
ing SADT. For comparison purposes, the Stephenson
nomogram, which predicts the likelihood of developing
BF post-SRT based on eleven clinical and pathologic
variables, had a c-index value of 0.69 in the dataset from
which the nomogram was derived [1] and a c-index of
0.71 in the dataset from which our presented data was
extracted. The fact that PSADT prior to the initiation of
SADT demonstrates similar predictive accuracy for the
development of PCSM and OM following BF post-SRT
highlights its clinical importance.
Our findings contribute to a growing body of work
identifying the potential benefits of initiating SADT
while patients have less advanced disease. Previous stud-
ies examining the benefits of initiating SADT early in
the disease course for patients experiencing BF without
metastatic disease are solely retrospective and performed
in the post-RP or post-definitive RT settings [7-11,21]. In
one such study, Moul et al. demonstrated the ability of
SADT initiation to delay the development of metastasis
in high-risk patients with PSA-only failure post-RP [21].
Several other retrospective studies have shown improvedoverall survival when SADT is started early in the course
of recurrent disease following BF post-definitive RT
[7-11]. Our results are similar to those reported by
Mydin et al. who were able to show that patients with a
pre-SADT PSA ≤10 ng/mL in the absence of DM had
improved overall survival post-definitive RT in a second-
ary analysis of Irish Clinical Oncology Research Group
97–01 [7]. However, PSADT prior to the initiation of
SADT was not prognostic for overall survival on multi-
variate analysis while timing of SADT administration
based on PSA level and presence or absence of DM at
initiation of SADT was prognostic for this endpoint [7]. In
contrast, Tenenholz et al. have previously shown PSADT
prior to the initiation of SADT to be the most powerful
predictor of overall survival and disease-specific survival
in a retrospective analysis of patients experiencing BF
post-definitive RT [9]. Thus, findings regarding whether
PSA or PSADT prior to starting SADT is a superior prog-
nostic factor for outcomes post-definitive RT are mixed.
Our results suggest that a PSADT <3 months prior to
starting SADT is more prognostic for risk of PCSM and
OM than the pre-SADT PSA level in the post-SRT setting.
This is not surprising considering that patients post-
prostatectomy should have uniformly low PSA levels, and
those harboring aggressive disease may develop short
PSADTs even before their PSA levels have a chance to
become markedly elevated once again. Another prognostic
factor that has been utilized to assess clinical risk is the
IBF after the start of SRT [19], which likely has some over-
lap with PSADT in that they may be measuring similar
biological processes. In the current analysis, it appeared
that a very short PSADT still added significant clinical
value when including both of these metrics in our multi-
variate Cox proportional hazards models.
As previously discussed, the inherent limitations to this
study secondary to its retrospective design warrant further
validation of our findings. A second limitation of this
analysis is that we were unable to assess toxicity related to
the use of SADT. The potential negative health effects of
ADT and ADT’s adverse effects on quality of life must be
considered when contemplating the appropriate clinical
context for its initiation. For instance, long-term use of
ADT is known to increase the risk of experiencing a
skeletal fracture and is associated with a higher risk
of developing type 2 diabetes mellitus [22]. Additionally,
ADT puts one at a higher risk for mortality secondary to
cardiovascular disease and is known to cause vasomotor
hot flashes and sexual side effects that can be associated
with a lower quality of life [22,23]. Thus, the administra-
tion of ADT is not benign and the decision to initiate this
treatment should be made after carefully considering the
potential risks and benefits of this therapeutic inter-
vention. Nevertheless, the possibility that survival may be
prolonged by initiating SADT when patients have less
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an attractive option, especially in high-risk patients
such as ours who have exhausted localized treatment
options [6].Conclusions
Overall, our results suggest that initiating SADT while
patients have less advanced disease following BF post-
SRT may be a sensible treatment option associated with
a decreased risk of PCSM and OM. However, obser-
vation may be a reasonable alternative for patients with
especially long PSADTs given their very low risk of
experiencing PCSM. Furthermore, a PSADT <3 months
before the initiation of SADT appears to significantly
predict an increased risk of PCSM and OM for patients
with biochemically recurrent disease following SRT. Fu-
ture prospective studies examining the optimal clinical
context for starting SADT post-SRT should consider
using the development of a short PSADT as a condition
for initiation of SADT given the significant ability of
pre-SADT PSADT <3 months to predict mortality in our
analysis.
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